Current and future disease-modifying therapies in multiple sclerosis

International Journal of Clinical Practice

Volumn 64, Issue 5, 2010, Pages 637-650

  Lim, S Y ^a   Constantinescu, C S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; BG 00012; CAMMS 223; CLADRIBINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FINGOLIMOD; FIRATEGRAST; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADD ON THERAPY; AUTOIMMUNE DISEASE; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG TOLERABILITY; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HAIRY CELL LEUKEMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HERPES SIMPLEX; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM; INFECTION; INJECTION SITE REACTION; LYMPHOCYTOPENIA; LYMPHOMA; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN CANCER; SKIN DISEASE; SKIN MANIFESTATION; THERAPY EFFECT; THYROID DISEASE; UNSPECIFIED SIDE EFFECT; UVEITIS; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DESIGN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; RECURRENCE;

EID: 77949412549     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02261.x     Document Type: Review

References (142)

1. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112(Pt 1): 133-46.
2. Kebir H, Kreymborg K, Ifergan I et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13: 1173-5.
3. Cross AH, Trotter JL, Lyons J. B cells and antibodies in CNS demyelinating disease. J Neuroimmunol 2001; 112: 1-14.
4. Double-masked trial of azathioprine in multiple sclerosis. British and Dutch multiple sclerosis azathioprine trial group. Lancet 1988; 2: 179-83.
5. Yudkin PL, Ellison GW, Ghezzi A et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051-5.
6. La Mantia L, Milanese C, Mascoli N et al. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev. 2007, Issue 1: CD002819.
7. Alam J, Goelz S, Rioux P et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers. Pharm Res 1997; 14: 546-9.
8. Dhib-Jalbut S. Mechanisms of interferon beta action in multiple sclerosis. Mult Scler 1997; 3: 397-401.
9. Bornstein MB, Miller A, Slagle S et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 7: 408-14.
10. Dhib-Jalbut S. Glatiramer acetate (copaxone) therapy for multiple sclerosis. Pharmacol Ther 2003; 98: 245-55.
11. Gran B, Tranquill LR, Chen M et al. Mechanisms of immuno-modulation by glatiramer acetate. Neurology 2000; 55: 1704-14.
12. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
13. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing ? remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
14. Jacobs LD, Cookfair DL, Rudick RA et al., The Multiple Sclerosis Collaborative Research Group (MSCRG) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
15. Johnson KP, Brooks BR, Cohen JA et al., The Copolymer 1 Multiple Sclerosis Study Group Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995; 45: 1268-76.
16. Freedman MS, Hughes B, Mikol DD et al. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur Neurol 2008; 60: 1-11.
17. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med 2002; 162: 2161-9.
18. Mikol DD, Barkhof F, Chang P et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7: 903-14.
19. O'Connor P, Arnason B, Comi G et al. Interferon Beta-1b 500 mcg, Interferon Beta-1b 250 mcg and Glatiramer Acetate: Primary Outcomes of the Betaferon® ? Betaseron® Efficacy Yielding Outcomes of a New Dose Study. Abstract from the American Academy of Neurology (AAN) 60th Annual Meeting. Chicago, IL, 2008. Abstract No: LBS.004.
20. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS ? MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94.
21. Rudick RA, Simonian NA, Alam JA et al., Multiple Sclerosis Collaborative Research Group (MSCRG). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998; 50: 1266-72.
22. Sorensen PS, Koch-Henriksen N, Ross C et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-9.
23. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology 1998; 51: 1698-702.
24. Pozzilli C, Antonini G, Bagnato F et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 2002; 249: 50-6.
25. Sorensen PS, Mellgren SI, Svenningsson A et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009; 8: 519-29.
26. Ravnborg M. A Multi-Centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Methylprednisolone (MP) in Combination with Interferon-b-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). Abstract from the 61st Annual Meeting of the American Academy of Neurologists (AAN). Seattle, WA, 2009. Abstract No: LB3.002.
27. Compston A, Dick J, Leigh N et al. ABN Guidelines for Treatment of Multiple Sclerosis with Beta-Interferon and Glatiramer acetate. London, UK: Association of British Neurologists, 2007.
28. The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999; 53: 679-86.
29. Blumhardt LD. Once weekly interferon beta for multiple sclerosis is superseded by higher and more frequent dosing. Int J Clin Pract Suppl 2002: 9-16.
30. Leger OJ, Yednock TA, Tanner L et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997; 8: 3-16.
31. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005; 4: 510-8.
32. Tubridy N, Behan PO, Capildeo R et al., The UK Antegren Study Group The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology 1999; 53: 466-72.
33. Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
34. O'Connor PW, Goodman A, Willmer-Hulme AJ et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004; 62: 2038-43.
35. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
36. Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23.
37. Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-8.
38. Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-33.
39. Biogen Idec Inc. TYSABRI update; 2009 24th July. http://www.biogenidec. com/site/tysabri-information-center.html (accessed August 2009).
40. Thompson JP, Noyes K, Dorsey ER et al. Quantitative risk-benefit analysis of natalizumab. Neurology 2008; 71: 357-64.
41. Calabresi PA, Giovannoni G, Confavreux C et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69: 1391-403.
42. Ismail A, Kemp J, Sharrack B. Melanoma complicating treatment with natalizumab (Tysabri) for multiple sclerosis. J Neurol 2009; 256: 1771-2.
43. Shenkenberg TD, Von Hoff DD. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 1986; 105: 67-81.
44. Edan G, Miller D, Clanet M et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-8.
45. Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-25.
46. Fidler JM, DeJoy SQ, Gibbons JJ Jr. Selective immuno-modulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986; 137: 727-32.
47. Fidler JM, DeJoy SQ, Smith FR 3rd, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986; 136: 2747-54.
48. Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004;63 (12 Suppl 6): S15-8.
49. Watson CM, Davison AN, Baker D et al. Suppression of demyelination by mitoxantrone. Int J Immunopharmacol 1991; 13: 923-30.
50. Lublin FD, Lavasa M, Viti C, Knobler RL. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987; 45: 122-8.
51. Krapf H, Morrissey SP, Zenker O et al. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005; 65: 690-5.
52. Rizvi SA, Zwibel H, Fox EJ. Mitoxantrone for multiple sclerosis in clinical practice. Neurology. 2004;63 (12 Suppl 6): S25-7.
53. Ramtahal J, Jacob A, Das K, Boggild M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 2006; 253: 1160-4.
54. Ghalie RG, Edan G, Laurent M et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59: 909-13.
55. Martinelli V. Incidence of Acute Leukaemia in Multiple Sclerosis Patients Treated with Mitoxandrone: A Multicentre Retrospective Italian Study. Abstract from the 61st Annual Meeting of the American Academy of Neurology (AAN). Seattle, WA, 2009.
56. Ghalie RG, Mauch E, Edan G et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002; 8: 441-5.
57. Voltz R, Starck M, Zingler V et al. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler 2004; 10: 472-4.
58. Moreau T, Coles A, Wing M et al. CAMPATH-IH in multiple sclerosis. Mult Scler 1996; 1: 357-65.
59. Coles A, Deans J, Compston A. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 2004; 106: 270-4.
60. Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-801.
61. Coles AJ, Wing M, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691-5.
62. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
63. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6.
64. Tintore M, Rovira A, Rio J et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008; 70(13 Pt 2): 1079-83.
65. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-88.
66. Aksoy S, Harputluoglu H, Kilickap S et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48: 1307-12.
67. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 2009; 113: 4834-40.
68. Serafini B, Rosicarelli B, Magliozzi R et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14: 164-74.
69. Magliozzi R, Howell O, Vora A et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130 (Pt 4): 1089-104.
70. Monson NL, Cravens PD, Frohman EM et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005; 62: 258-64.
71. Hawker KS, O'Connor P, Freedman MS et al. Efficacy and Safety of Rituximab in Patients with Primary Progressive Multiple Sclerosis: Results of A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Presented at the World Congress on Treatment and Research in Multiple Sclerosis: 2008 Joint Meeting of the American, European, and Latin America Committees on Treatment and Research in Multiple Sclerosis. Montreal, Quebec, 2008.
72. Cree BA, Lamb S, Morgan K et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270-2.
73. Jacob A, Weinshenker BG, Violich I et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443-8.
74. Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 2007; 27: 1-18.
75. Nussenblatt RB, Fortin E, Schiffman R et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I ? II clinical trial. Proc Natl Acad Sci U S A 1999; 96: 7462-6.
76. Waldmann TA, O'Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998; 10: 507-12.
77. Bielekova B, Catalfamo M, Reichert-Scrivner S et al. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 5941-6.
78. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004; 56: 864-7.
79. Bielekova B, Richert N, Howard T et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 2004; 101: 8705-8.
80. Bielekova B, Howard T, Packer AN et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66: 483-9.
81. Rose JW, Burns JB, Bjorklund J et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69: 785-9.
82. Ali EN, Stazzone LA, Brown BA et al. Daclizumab in the Treatment of Patients with Multiple Sclerosis. Presented at the 59th Annual Meeting of the American Academy of Neurology. Boston, MA, 2007.
83. Montalban X, Wynn D, Kaufman M et al. Preliminary CHOICE results: a Phase 2, randomised, double-blind, placebo-controlled multicentre study of subcutaneous daclixumab in patients with active, relapsing forms of multiple sclerosis on interferon B. Presented at the 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis. Prague, Czech Republic, 2007.
84. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004; 4: 1019-25.
85. Mehling M, Brinkmann V, Antel J et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008; 71: 1261-7.
86. Fujino M, Funeshima N, Kitazawa Y et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305: 70-7.
87. Webb M, Tham CS, Lin FF et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 2004; 153: 108-21.
88. Miron VE, Jung CG, Kim HJ et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63: 61-71.
89. Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-40.
90. Cohen J, Pelletier J, Kappos L et al. Oral Fingolimod (FTY720) Versus Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis: Results from a Phase III Study (TRANSFORMS). Presented at the 61st Annual Meeting of the American Academy of Neurology (AAN). Seattle, WA, 2009.
91. Leypoldt F, Munchau A, Moeller F et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 2009; 72: 1022-4.
92. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737-43.
93. Sipe JC, Romine JS, Koziol JA et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13.
94. Rice GP, Filippi M, Comi G, Cladribine MRI Study Group. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000; 54: 1145-55.
95. Romine JS, Sipe JC, Koziol JA et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111: 35-44.
96. Giovannoni G. Clinical Efficacy of Cladribine Tablet Therapy in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the CLARITY Study, a 96-week, Phase III, Double-Blind, Placebo-Controlled Trial. Presented at the 61st Annual Meeting of the American Academy of Neurology (AAN). Seattle, WA, 2009.
97. Tallantyre E, Evangelou N, Constantinescu CS. Spotlight on teriflunomide. Int MS J 2008; 15: 62-8.
98. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000; 47: 273-89.
99. Merrill JE, Hanak S, Pu SF et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009; 256: 89-103.
100. Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide - mechanisms independent of pyrimidine depletion. J Leukoc Biol 2004; 76: 950-60.
101. O'Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894-900.
102. Kalden JR, Schattenkirchner M, Sorensen H et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 2003; 48: 1513-20.
103. Emery P, Breedveld FC, Lemmel EM et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 655-65.
104. Brunmark C, Runstrom A, Ohlsson L et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130: 163-72.
105. Polman C, Barkhof F, Sandberg-Wollheim M et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64: 987-91.
106. Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085-92.
107. Schimrigk S, Brune N, Hellwig K et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006; 13: 604-10.
108. Calabrese V, Ravagna A, Colombrita C et al. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res 2005; 79: 509-21.
109. Li J, Johnson D, Calkins M et al. Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. Toxicol Sci 2005; 83: 313-28.
110. Hubbs AF, Benkovic SA, Miller DB et al. Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am J Pathol 2007; 170: 2068-76.
111. de Jong R, Bezemer AC, Zomerdijk TP et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26: 2067-74.
112. Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997; 234: 19-23.
113. Kappos L, Gold R, Miller DH et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372: 1463-72.
114. Jackson DY. Alpha 4 integrin antagonists. Curr Pharm Des 2002; 8: 1229-53.
115. Ormerod IE, McDonald WI, du Boulay GH et al. Disseminated lesions at presentation in patients with optic neuritis. J Neurol Neurosurg Psychiatry 1986; 49: 124-7.
116. Martinelli V, Comi G, Filippi M et al. Paraclinical tests in acute-onset optic neuritis: basal data and results of a short follow-up. Acta Neurol Scand 1991; 84: 231-6.
117. Ford B, Tampieri D, Francis G. Long-term follow-up of acute partial transverse myelopathy. Neurology 1992; 42: 250-2.
118. Barkhof F, Filippi M, Miller DH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120 (Pt 11): 2059-69.
119. Swanton JK, Fernando K, Dalton CM et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006; 77: 830-3.
120. Tintore M, Rovira A, Rio J et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67: 968-72.
121. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295-302.
122. Zivadinov R, Sepcic J, Nasuelli D et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70: 773-80.
123. Kuhlmann T, Lingfeld G, Bitsch A et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain. 2002; 125 (Pt 10): 2202-12.
124. Fisniku LK, Brex PA, Altmann DR et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131 (Pt 3): 808-17.
125. Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.
126. Kinkel R, Dontchev M, Tanner J et al. CHAMPIONS EXTENSION Study: 10-Year Follow-up After a Clinically Isolated Syndrome (CIS) Involving High-Risk Patients. Abstract from the 61st Annual Meeting of the American Academy of Neurology (AAN). Seattle, WA, 2009. Abstract No: P06.137.
127. Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
128. Kappos L, Polman CH, Freedman MS et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-9.
129. Clerico M, Faggiano F, Palace J et al. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008, Issue 2: CD005278.
130. Comi G, Filippi M. Treatment with Glatiramer Acetate Delays Conversion to Clinically Definite Multiple Sclerosis (CDMS) in Patients with Clinically Isolated Syndromes (CIS). Presented at the American Academy of Neurology (AAN) 60th Annual Meeting. Chicago, IL, 2008.
131. Pittock SJ, Mayr WT, McClelland RL et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004; 62: 51-9.
132. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
133. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788-95.
134. SPECTRIMS Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 2001; 56: 1496-504.
135. Cohen JA, Cutter GR, Fischer JS et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-87.
136. Leary SM, Miller DH, Stevenson VL et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44-51.
137. Montalban X. Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult Scler 2004;10 (Suppl. 1): S62; discussion-4.
138. Wolinsky JS, Narayana PA, O'Connor P et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14-24.
139. Kita M, Cohen J, Fox R. A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis (abstract). Neurology 2004; 000: A99.
140. Pohlau D, Przuntek H, Sailer M et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 2007; 13: 1107-17.
141. Hommes OR, Sorensen PS, Fazekas F et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364: 1149-56.
142. Saccardi R, Kozak T, Bocelli-Tyndall C et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for blood and marrow transplantation autoimmune diseases working party database. Mult Scler 2006; 12: 814-23.